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To the Editor:
The advent of the first tyrosine kinase inhibitor (TKI)
imatinib in 2001—targeting the BCR-ABL1 oncoprotein—
revolutionized the management of chronic myeloid leuke-
mia (CML). Trials of imatinib and subsequent TKIs in CML
have shown excellent survival outcomes. However, the
broad applicability of trial results in daily practice has its
limits because of the patient selection criteria dictated by
study protocols—especially among elderly, often comorbid
patients who are generally underrepresented in pivotal CML
trials [1].
Population-based studies can inform how changing
treatment practices affect population-level survival. The
paucity of representative population-based studies in CML
is comparatively outdated and does not explicitly provide a
comprehensive apprehension on treatment or survival
among different older age groups, as patients are frequently
combined into one age group or broad ranges of age [2–5].
Therefore, to complement and extend on prior population-
based research, we conducted a comprehensive, nationwide,
population-based study to assess trends in primary treatment
and survival among elderly CML patients diagnosed during
a 28-year period in the Netherlands.
We selected all CML patients aged ≥ 70 years diagnosed
between 1989 and 2017—with survival follow-up through
January 1, 2019—from the nationwide population-based
Netherlands Cancer Registry (NCR) using International
Classification of Diseases for Oncology morphology codes
9863 and 9875. Nationwide since 1989, the NCR has an
overall coverage of >95% of all newly diagnosed malig-
nancies in the Netherlands [6]. The NCR relies on case
notification through the Nationwide Network of Histo-
pathology and Cytopathology, and the Nationwide Registry
of Hospital Discharges (i.e., inpatient and outpatient dis-
charges). Information on the dates of birth and diagnosis,
sex, prior malignancies, vital statistics (i.e., alive, emigra-
tion, or death), and first-line anti-CML treatment—defined
as chemotherapy, immunotherapy, or TKI—was available
for individual patients. This information is collected by
trained registrars of the NCR through retrospective medical
records review. Data on the use of TKI therapy and the
specific therapeutic agent were registered in the NCR for
patients diagnosed from 2007 and 2014, respectively. Of
note, the use of TKI therapy before the calendar year 2007
was recorded in the NCR as anti-CML treatment.
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Patients were divided into four age groups (70–74,
74–79, 80–84, and ≥85 years) and three calendar periods
(1989–2000, 2001–2008, and 2009–2017). The first
calendar period represents the pre-TKI era, the second and
third period the era in which imatinib and subsequent
generations of TKIs were introduced in daily practice,
respectively.
Relative survival (RS) was calculated to estimate
disease-specific survival as per the cohort methodology. RS
was calculated up to 5 years after diagnosis according to the
calendar period of diagnosis and age at diagnosis and
measured from diagnosis to death, emigration, or end of
follow-up (January 1, 2019), whichever occurred first. RS is
the overall survival in the patient cohort divided by the
expected survival of a comparable group from the general
population, matched to the patients through age, sex, and
period [7]. The expected survival was calculated from
Dutch population life tables—stratified by age, sex, and
period—according to the Ederer II methodology [8]. Pois-
son regression was applied to investigate linear trends in RS
over time and the relative excess risk of mortality [9]. A P <
0.05 indicates statistical significance. The Privacy Review
Board of the NCR approved the use of anonymous data for
this study.
Age at diagnosis and calendar period of diagnosis
Primary therapy Column percentage
Anti-CML therapy 61 83 - 56 69 - 54 70 - 36 47 -
TKI - - 93 - - 93 - - 80 - - 74
CT alone - 4 2 - 6 3 - - 13 - 3 6
Other/unknown therapy 2 - - 4 1 - 2 1 - 3 2 2
No therapy 37 13 5 40 24 4 44 29 7 62 47 17
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70-74 75-79 80-84 ≥85
Anti-CML therapy TKI CT alone Other/unknown therapy No therapy
Primary therapy Imatinib Nilotinib Dasatinib Hydroxyurea No therapy Total
Age, years N (%) N (%) N (%) N (%) N (%) N
70-74 62 (68) 15 (16) 12 (13) 0 - 2 (2) 91
75-79 45 (80) 5 (9) 6 (11) 0 - 0 - 56
80-84 33 (67) 4 (8) 6 (12) 3 (6) 3 (6) 49
≥85 18 (78) 2 (9) 0 - 1 (4) 2 (9) 23
Total 158 (72) 26 (12) 24 (11) 4 (2) 7 (3) 219
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Fig. 1 Primary treatment of
elderly patients with chronic
myeloid leukemia in the
Netherlands. a Shows
information on primary therapy
according to age at diagnosis
and calendar period of diagnosis
among patients diagnosed
between 1989 and 2017.
b Shows information on primary
therapy according to age at
diagnosis among patients
diagnosed between 2014 and
2017. The table in (a) presents
the proportion of patients
receiving a particular treatment
within a specific age group and
calendar period. The absolute
number of patients within a
specific age group and calendar
period presented in (a) is shown
in Supplementary Table 3. The
table in (b) presents the absolute
number and proportion of
patients receiving a particular
treatment within a specific
age group.
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A total of 1525 CML patients aged ≥ 70 years were
included in the study (median age, 77 years; range 70–95
years; 56% males; and 11% with a prior malignancy). The
characteristics of these patients are presented in Supple-
mentary Table 1. Overall, 31%, 32%, 22%, and 15% of
patients were aged 70–74, 75–79, 80–84, and ≥85 years,
respectively.
Figure 1a presents information on primary treatment
according to age at diagnosis and calendar period of
diagnosis. The application of anti-CML therapy increased
over time across all age groups. Data of patients diagnosed
during 2009–2017 showed that 93%, 93%, 80%, and 74%
of the patients across the four age groups received a TKI,
respectively. Detailed data on primary therapy among 219
patients diagnosed during 2014–2017 are shown in Fig. 1b.
Figure 2 shows RS according to age at diagnosis and
calendar period of diagnosis. One-, 3-, and 5-year RS
improved significantly over time across all age groups.
Fig. 2 Relative survival of
elderly patients with chronic
myeloid leukemia in the
Netherlands according to age
at diagnosis and calendar
period of diagnosis,
1989–2017. Relative survival
rates (RSR) are shown for the
following age categories: a
70–74 years, b 75–79 years,
c 80–84 years, and d ≥85 years.
The table presents the projected
1-, 3-, and 5-year RSR with 95%
confidence intervals (CIs)
according to age at diagnosis
and calendar period of
diagnosis. *P value for
likelihood ratio test assessing
linear trends from the period
1989–2000 to the period
2009–2017.
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Nevertheless, patients across all age groups experienced
ongoing excess mortality—as compared with the general
population—in the most recent period (2009–2017). Fur-
thermore, improvement in RS among patients aged ≥ 75
lagged behind those aged 70–74 years in the period between
1989–2000 and 2001–2008. The most pronounced
improvement in RS among patients aged ≥ 75 years took
place between 2001–2008 and 2009–2017, especially
among patients aged ≥ 85 years.
Next, we analyzed the relative excess risk of mortality
within five years after CML diagnosis in a multivariable
model (Supplementary Table 2). Overall, when simulta-
neously adjusted for sex, age at diagnosis, calendar period
of diagnosis, and a prior malignancy, patients diagnosed in
2009–2017 had 63% lower excess mortality, as compared
with patients diagnosed in 2001–2008 (excess mortality
ratio, 0.37; 95% confidence interval [CI]; 0.29–0.50; P <
0.001). However, after additional adjustment for primary
therapy, the effect of calendar period lost statistical sig-
nificance. This finding suggests that changes in the appli-
cation of primary therapy contributed to the improved
survival during 2009–2017. Lastly, older age and male sex
were independent predictors of poor prognosis.
In this nationwide, population-based study, we demon-
strated that RS among all age groups of CML patients
aged ≥ 70 years improved considerably after the introduc-
tion of imatinib in 2001. However, the improvement
between 1989–2000 and 2001–2008 among patients aged ≥
75 years was less pronounced compared with patients aged
70–74 years. The improvement in the former age group was
most pronounced between 2001–2008 and 2009–2017,
especially among patients aged ≥ 85 years. This observation
might suggest that patients aged ≥ 75 years did not imme-
diately gain benefit from the advances in CML
management.
Our findings that survival improvements lag in the oldest
age groups are mostly congruent with and extend on find-
ings from the few available population-based studies in
CML [2, 3, 10, 11]. In the USA and England, 5-year RSRs
(95% CI) among patients aged 65–74 years increased
between 2001–2005 and 2006–2010 from 42% (36–48%) to
58% (52–64%) and from 40% (35–46%) to 60% (55–65%),
respectively. In contrast, the corresponding rates among
patients aged ≥ 75 years increased from only 25% (21–30%)
to 33% (28–38%) and from 18% (14–21%) to 26%
(22–30%), respectively [2]. Similarly, in Sweden, 5-year
RSRs (95% CI) improved for patients aged 70–79 and >79
years from 24% (17–33%) to 75% (61–86%) and from 6%
(1–18%) to 25% (10–47%) between 1987–1993 and
2001–2008, respectively [10]. Of note, the RSRs in the
Netherlands seems to lag compared with the Swedish rates.
However, registration practices and the wideness of the CIs
should be strongly considered when comparing survival
rates across countries [12]. Therefore, a firm conclusion
regarding potential survival disparities cannot be made.
This topic provides an avenue for future research.
Congruent with our study, detailed data of the Swedish
CML Registry among patients diagnosed during
2002–2010 showed that the application of TKIs increased
over time among patients aged ≥ 70 years [11]. Furthermore,
during 2007–2009, 85% and 79% of patients aged 70–79
and >79 years received first-line TKI, respectively. Vir-
tually all patients aged ≥ 70 years diagnosed during
2014–2017 received first-line TKI, except for seven
patients. The following reasons for not prescribing a TKI
were reported: patients’ preferences (n= 3), short life-
expectancy (n= 1), functional status (n= 1), comorbidities
(n= 1), and unknown reason (n= 1).
Despite these encouraging findings on survival
improvement, elderly CML patients experience consider-
able excess mortality in contemporary clinical practice—
particularly those aged ≥ 80 years. There are several possi-
ble contributing factors. Elderly patients may experience
greater toxicities of TKI treatment due to comorbidities,
which, in turn, might result in decreased adherence or dis-
continuation. Therefore, physicians were possibly reticent
to offer TKIs to elderly, often comorbid patients—espe-
cially in the early years following commercially available
imatinib. Whether the reticent application of TKI relates to
the patients’ comorbidity, frailty, desire, or other patient- or
physician-related characteristics is an area for future
research to further improve the care among the elderly.
Improvement in CML management and supportive mea-
sures is desired, in the view of the rapid growth of the aging
population, resulting in an increased incidence of CML
among the elderly [13]. The current study provides a
benchmark to assess whether excess mortality among
elderly patients will decline in the years ahead.
The strength of our study includes the utilization of a
nationwide population-based cohort with a relatively large
number of patients, long-term study period, and compre-
hensive information on primary therapy. Therefore, unlike
most population-based studies, we could directly link
changing treatment practices with improvements in survi-
val. Limitations of our study mainly pertain to the lack of
detailed information on the response, monitoring, and sub-
sequent treatment choices throughout most of the registry.
Collectively, in this nationwide, population-based study,
RS increased significantly over time among various age
groups of elderly CML patients. This improvement is likely
accounted for by the introduction and increased application
of TKIs since 2001. Nevertheless, elderly CML patients
continue to experience excess mortality in a contemporary
era with well-established TKI management. Forthcoming
studies should center on further reducing excess mortality in
this elderly population.
G. I. C. G. Ector et al.
Acknowledgements The authors would like to thank the registration
clerks of the Netherlands Cancer Registry (NCR) for their dedicated data
collection. The nationwide population-based NCR is maintained and
hosted by the Netherlands Comprehensive Cancer Organisation (IKNL).
Author contributions AGD designed the study; GICGE analyzed the
data; AGD supervised the data analyses; OV collected the data;
GICGE wrote the paper with contributions from all authors, who also
interpreted the data, and read, commented on, and approved the final
version of the paper.
Compliance with ethical standards
Conflict of interest GICGE: no conflict of interest. OV: no conflict of
interest. PEW: no conflict of interest. JJWMJ: Research Support
Novartis, BMS. Honoraria Abbvie, Novartis, Pfizer, Incyte. NMAB:
no conflict of interest. AGD: no conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Rohrbacher M, Berger U, Hochhaus A, Metzgeroth G, Adam K,
Lahaye T, et al. Clinical trials underestimate the age of chronic
myeloid leukemia (CML) patients. Incidence and median age of
Ph/BCR-ABL-positive CML and other chronic myeloproliferative
disorders in a representative area in Germany. Leukemia.
2008;23:602–4.
2. Pulte D, Redaniel MT, Bird J, Jeffreys M. Survival for patients
with chronic leukemias in the US and Britain: age-related dis-
parities and changes in the early 21st century. Eur J Haematol.
2015;94:540–5.
3. Krok-Schoen JL, Fisher JL, Stephens JA, Mims A, Ayyappan S,
Woyach JA, et al. Incidence and survival of hematological cancers
among adults ages ≥75 years. Cancer Med. 2018;7:3425–33.
4. Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G,
Levato L, et al. Differences among young adults, adults and elderly
chronic myeloid leukemia patients. Ann Oncol. 2015;26:185–92.
5. Mandal R, Bolt DM, Shah BK. Disparities in chronic myeloid
leukemia survival by age, gender, and ethnicity in pre- and post-
imatinib eras in the US. Acta Oncol. 2013;52:837–41.
6. Schouten LJ, Hoppener P, van den Brandt PA, Knottnerus JA,
Jager JJ. Completeness of cancer registration in Limburg, The
Netherlands. Int J Epidemiol. 1993;22:369–76.
7. Dickman PW, Adami HO. Interpreting trends in cancer patient
survival. J Intern Med. 2006;260:103–17.
8. Ederer F, Heise H. Instructions to IBM 650 programmers in
processing survival computations. Methodological Note No. 10.
End Results Evaluation Section. National Cancer Institute:
Bethesda, MD, 1959.
9. Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression
models for relative survival. Stat Med. 2004;23:51–64.
10. Bjorkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sjo-
berg J, et al. Success story of targeted therapy in chronic myeloid
leukemia: a population-based study of patients diagnosed in
Sweden from 1973 to 2008. J Clin Oncol. 2011;29:2514–20.
11. Hoglund M, Sandin F, Hellstrom K, Bjoreman M, Bjorkholm M,
Brune M, et al. Tyrosine kinase inhibitor usage, treatment out-
come, and prognostic scores in CML: report from the population-
based Swedish CML registry. Blood. 2013;122:1284–92.
12. Sant M, Minicozzi P, Mounier M, Anderson LA, Brenner H,
Holleczek B, et al. Survival for haematological malignancies in
Europe between 1997 and 2008 by region and age: results of
EUROCARE-5, a population-based study. Lancet Oncol.
2014;15:931–42.
13. Huang X, Cortes J, Kantarjian H. Estimations of the increasing
prevalence and plateau prevalence of chronic myeloid leukemia in
the era of tyrosine kinase inhibitor therapy. Cancer.
2012;118:3123–7.
Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a. . .
